泻肺利水方联合化疗治疗结核性胸膜炎疗效及肺功能、免疫功能影响

摘要/Abstract

摘要： 目的探讨泻肺利水方联合化疗治疗结核性胸膜炎疗效及肺功能、免疫功能影响。方法选择2021年6月—2022年7月陕西省结核病防治院（陕西省第五人民医院）收治的96例结核性胸膜炎患者为研究对象,按随机数表法分为对照组和试验组,每组48例,对照组仅予以化疗治疗,试验组在对照组基础上采用泻肺利水方治疗。比较两组治疗前后胸膜厚度、胸水引流量和吸收时间、肺功能及外周血Th1细胞、Th2细胞、Th17细胞、Treg细胞的变化。结果治疗前,两组胸水引流量、胸膜厚度比较,差异无统计学意义（P>0.05）,治疗后均降低,且试验组低于对照组（P<0.05）;试验组胸水吸收时间明显短于对照组（P<0.05）;试验组总有效率高于对照组,差异无统计学意义（P>0.05）。两组治疗前后FEV₁% pred、FVC% pred、FEV₁/FVC% pred、RV% pred、TLC% pred比较,差异无统计学意义（P>0.05）,两组治疗后FEV₁% pred、FVC% pred、TLC% pred均高于治疗前,FEV₁/FVC% pred、RV% pred均低于治疗前（P<0.05）。治疗前,两组Th1细胞、Th2细胞、Th1/Th2、Th17细胞、Treg细胞、Th17/Treg比例比较,差异无统计学意义（P>0.05）,治疗后,两组Th1细胞、Th2细胞、Th1/Th2、Th17细胞、Treg细胞、Th17/Treg比例均降低,Th2细胞、Treg细胞比例无明显变化,差异无统计学意义（P>0.05）,而试验组Th1细胞、Th1/Th2、Th17及Th17/Treg明显低于对照组（P<0.05）。结论与单纯化疗相比,联合泻肺利水方治疗结核性胸膜炎能进一步促进胸水更快吸收,并改善免疫功能,但并不能提高总体疗效以及改善肺功能。

关键词: 结核性胸膜炎, 化疗, 泻肺利水方, 肺功能, 免疫功能

Abstract: Objective To investigate the curative effect of Xiefei Lishui Recipe combined with chemotherapy on tuberculous pleurisy and its influence on pulmonary function and immune function. Methods A total of 96 patients with tuberculous pleurisy admitted to Shaanxi Tuberculosis Prevention and Control Hospital (the Fifth People’s Hospital of Shaanxi Province) from June 2021 to July 2022 were selected and divided into two groups by random number table method, with 48 cases in each group. The control group was treated only with chemotherapy, while the study group was treated with Xiefei Lishui Formula on the basis of the control group. The pleural thickness, pleural effusion drainage volume and absorption time before and after treatment were compared between the two groups lung function and peripheral blood Th1 cells, Th2 cells Th17 cells and Treg cells. Results There was no obvious difference in the pleural fluid flow between the two groups (P>0.05). The pleural thickness did not different between the two groups before treatment (P>0.05), decreased after treatment, and the experimental group was lower than the control group (P<0.05), and the pleural fluid absorption time in the experimental group was significantly shorter than that in the control group (P<0.05). The total response rate (95.83%) was higher than 89.58%, with no difference (P>0.05). Between FEV₁% pred, FVC% pred, FEV₁/FVC% Pred, RV% pred, TLC% pred before and after treatment (P>0.05), FEV₁% pred, FVC% pred, TLC% pred were higher than before treatment, and FEV₁/FVC% Pred, RV% pred were lower than before treatment (P<0.05). Th1 cells, Th2 cells, Th1/Th2, Th17 cells, Treg cells and Th17/Treg (P>0.05), after treatment, Th1 cells, Th1, and Treg cells (P>0.05), while Th1 cells, Th1/Th2, Th17 and Th17/Treg were significantly lower than the control group (P<0.05). Conclusion Compared with chemotherapy alone, the combination of Xiefei Lishui Recipe in the treatment of tuberculous pleurisy can further promote faster absorption of pleural fluid and improve immune function, but it can not improve the overall efficacy and improve pulmonary function.

Key words: tuberculous pleurisy, chemotherapy, Xiefei Lishui recipe, lung function, immunity

中图分类号:

R521.7

景凤英, 仵倩红. 泻肺利水方联合化疗治疗结核性胸膜炎疗效及肺功能、免疫功能影响[J]. 中华养生保健, 2023, 41(7): 20-23.

JING Feng-ying, WU Qian-hong. Effect of Xiefei Lishui Recipe Combined with Chemotherapy on Tuberculous Pleuritis and the Influence of Pulmonary Function and Immune Function[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(7): 20-23.

参考文献

[1] World Health Organization. Global tuberculosis report2019[EB/OL].(2020-10-14)[2022-12-29].https://www.who.int/publications/i/item/9789241565714.
[2] 杨新婷,关国英,王亚红,等.结核性胸膜炎的临床特征及诊断技术分析[J].中国防痨杂志,2017,39(11):1162-1168.
[3] 逄宇,熊瑜,丛林,等.中华医学会结核病学分会2018年全国结核病学术年会会议纪要[J].中华结核和呼吸杂志,2018,41(10):830-832.
[4] 王建卫,王强,李鼎,等.排石汤联合ESWL对输尿管结石患者临床疗效及炎性因子表达的影响[J].湖北中医药大学学报,2021,23(6):77-79.
[5] 王磊,马玲,乔庆东,等.输尿管软镜碎石术和体外冲击波碎石术治疗小于20 mm肾结石的临床疗效及影响因素分析[J].新乡医学院学报,2019,36(12):1141-1144.
[6] 中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识(2019年版)[J].中华结核和呼吸杂志, 2019, 42(10):733-749.
[7] 国家中医药管理局.中医病证诊断疗效标准:ZY/T 001.1~001.9-94[S].南京:南京大学出版社,1994:11.
[8] 中国人民解放军总后勤部卫生部.临床疾病诊断依据治愈好转标准[M].北京:人民军医出版社,1987:64.
[9] 郑磊,刘猛,贾立群.恶性胸腔积液中医证候及用药规律分析[J].北京中医药,2015,34(7):529-531.
[10] 陶思雨,姜石松,申元英,等.机体抗结核分枝杆菌的免疫机制研究进展[J].中国病原生物学杂志,2020,15(2):233-237.
[11] 阮洪云,李琦,陈效友,等.结核性胸膜炎患者化疗时是否加用糖皮质激素对肺功能动态变化的对比研究[J].中国防痨杂志,2021,43(1):58-63.
[12] 赵玉升,李伟洋,曹天佑,等.基于纳米技术研究葶苈子炭治疗急性肺损伤的物质基础及其机制[J].中草药,2021,52(20):6188-6196.
[13] 杨长福,刘杨,徐昌君,等.药对桑白皮、百部提取物对小鼠肺纤维化的干预作用[J].中药材,2017,40(6):1448-1452.
[14] 王艳宏,樊建,赵娟萍,等.白芥子散及其拆方对过敏性哮喘大鼠神经肽的影响[J].中成药,2019,41(9):2223-2228.
[15] 王玉芝,黄倩,李成文.不同类型T淋巴细胞在结核性胸膜炎发生发展中作用的研究进展[J].山东医药,2017,57(38):103-106.
[16] 王蓉,马腾茂,刘飞,等.防己的药理作用及临床应用研究进展[J]. 中国中药杂志, 2017,42(4):634-639.
[17] 费晓雅,蒯仂,李秀丽,等.麻黄主治效用探微[J].世界中医药,2020,15(16):2503-2506.